Terence R. Flotte, MD

In a memo to the UMass Medical School community, Chancellor Michael F. Collins and Dean Terence R. Flotte say racism is a public health crisis and outline changes underway at UMMS.

Two young children with Tay-Sachs disease were treated safely at UMass Memorial Medical Center with a gene therapy developed at UMass Medical School and, in one case, the child’s condition has stabilized, according to an interview published by WBUR with Terence R. Flotte, MD.

Preliminary data from an expanded access study of an investigational gene therapy in two patients with infantile Tay-Sachs disease indicates the potential to modify the rate of disease progression, according to a recent report presented in Barcelona by Terence R. Flotte, MD.

Reforms are needed to ensure the integrity of the medical residency program selection process, according to commentary in the journal Academic Medicine by Chancellor Michael F. Collins and colleagues at UMass Medical School.

The Toronto-based Blu Genes Foundation, which is dedicated to developing gene therapies for rare disease, has given $1.4 million to UMass Medical School to advance a Phase I/II clinical trial for Tay-Sachs. Miguel Sena-Esteves, PhD, Terence Flotte, MD, Heather Gray-Edwards, PhD, DVM, and colleagues at  Auburn University are leading the research.

Dean Terence R. Flotte served as senior author on a call to action published in Academic Medicine, titled, “It is time for zero tolerance for sexual harassment in academic medicine.”

A new institute for rare diseases research at UMass Medical School will build on the school’s already substantial accomplishments in the fields of gene therapy, RNA biology and RNAi technology to accelerate the development of novel therapeutics for a host of disorders.

Terence R. Flotte, MD, and Guangping Gao, PhD, attended the 12th Annual International Conference on Rare Diseases & Orphan Drugs in Bejing, China. 

Data demonstrating sustained protein expression five years after a single intramuscular injection of a gene-based therapy for the treatment of alpha-1 antitrypsin (AAT) deficiency also shows improvements in multiple indicators of AAT biological activity. The study, led by Dean Terence R. Flotte, appears in the June issue of Molecular Therapy.

Terence R. Flotte, MD, delivered the Worcester District Medical Society’s 221st Annual Oration, “A Glass (more than) Half Full: Top Ten Reasons to Be Optimistic About the Next 220 Years of Medicine in Worcester,” on Wednesday, Feb. 8, at the Beechwood Hotel.